# A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.

> **NCT00531804** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 60 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** gantenerumab

## Key facts

- **NCT ID:** NCT00531804
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531804, "A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00531804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*